Characteristics and outcome of responding patients
| WHO classification . | Marrow blasts, % . | Karyotype . | Clinical response . | Time to relapse, mo* . | Survival time, mo† . |
|---|---|---|---|---|---|
| AML without maturation (M1) | 35 | Pretreatment (no follow-up available): 46,XX,del(5)(q31q33)[14]/46,XX[6] | CRi | 2.8 | 15.1 (died) |
| AML otherwise categorized | 90 | Pretreatment: 55,XY,+Y,+4,-5,add(7)(q11.2),+8, +9,+10, +11,+14,der(17)t(17;18) (p11.2;q11.2), +22, +marx2[5]/54∼55,sl,-der(17)t(17;18), +17,+18, +20,+21,-22,-marx2[cp12] | CRi | 0.9 | 2.8 (died) |
| Follow-up: 55,XY,+Y,+4,-5,add(7)(q11.2),+8, +9,+10, +11,+14,der(17)t(17;18) (p11.2;q11.2), +22, +marx2[2]/54,sl,-mar[4]/46,XY[12] | |||||
| AML otherwise categorized | 80 | Pretreatment (no follow-up available): 90–92, XXYY,del(5)(q13q33),-7,+13,+13,der(15) t(9;15)(q12;p11.2),-21,-21, +mar1, +mar2[6]/ 47,XY,+9[2]/46,XY[12] | CR | 13.8 (no report of relapse) | 15.6 (died) |
| AML otherwise categorized | 27 | Pretreatment: 44,XY,del(1)(p36.1),del(5) (q13q33),-7,-10,del(12)(p11.2p12),-20, +mar[11]/44,sl,del(11) (q14q23)[3]/46,XY[6] | CR | 5.3 | 6.7 (alive) |
| Follow-up: 46,XY[20] (only 1 process, inadequate for interpretation) | |||||
| AML with multilineage dysplasia | 45 | Pretreatment (no follow-up available): 46,XX,del(5)(q15q33)[15]/46,XX[5] | PR | 20.2 (no report of relapse) | 23.6 (alive) |
| WHO classification . | Marrow blasts, % . | Karyotype . | Clinical response . | Time to relapse, mo* . | Survival time, mo† . |
|---|---|---|---|---|---|
| AML without maturation (M1) | 35 | Pretreatment (no follow-up available): 46,XX,del(5)(q31q33)[14]/46,XX[6] | CRi | 2.8 | 15.1 (died) |
| AML otherwise categorized | 90 | Pretreatment: 55,XY,+Y,+4,-5,add(7)(q11.2),+8, +9,+10, +11,+14,der(17)t(17;18) (p11.2;q11.2), +22, +marx2[5]/54∼55,sl,-der(17)t(17;18), +17,+18, +20,+21,-22,-marx2[cp12] | CRi | 0.9 | 2.8 (died) |
| Follow-up: 55,XY,+Y,+4,-5,add(7)(q11.2),+8, +9,+10, +11,+14,der(17)t(17;18) (p11.2;q11.2), +22, +marx2[2]/54,sl,-mar[4]/46,XY[12] | |||||
| AML otherwise categorized | 80 | Pretreatment (no follow-up available): 90–92, XXYY,del(5)(q13q33),-7,+13,+13,der(15) t(9;15)(q12;p11.2),-21,-21, +mar1, +mar2[6]/ 47,XY,+9[2]/46,XY[12] | CR | 13.8 (no report of relapse) | 15.6 (died) |
| AML otherwise categorized | 27 | Pretreatment: 44,XY,del(1)(p36.1),del(5) (q13q33),-7,-10,del(12)(p11.2p12),-20, +mar[11]/44,sl,del(11) (q14q23)[3]/46,XY[6] | CR | 5.3 | 6.7 (alive) |
| Follow-up: 46,XY[20] (only 1 process, inadequate for interpretation) | |||||
| AML with multilineage dysplasia | 45 | Pretreatment (no follow-up available): 46,XX,del(5)(q15q33)[15]/46,XX[5] | PR | 20.2 (no report of relapse) | 23.6 (alive) |